Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05900856
Other study ID # p. t.REC/012/003570
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 9, 2023
Est. completion date August 9, 2023

Study information

Verified date March 2024
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

the aim of this study is to investigate the efficacy of ultrasound cavitation on static and dynamic balance in obese postnatal women with diastasis recti


Description:

Rectus diastasis defined as the widening of the linea alba by more than 2 cm at the midline. A great proportion of pregnant women are complaining from rectus diastasis during pregnancy reaching 100% of all women that may continue for years after delivery in 66% of women, and do not return to the first state automatically. This occurs due to a combination of physiologic, hormonal and mechanical factors, leading to reduction of abdominal muscle functional strength, increased low back pain out of increased lumbar hyperlordosis and postural instability, which may seriously disable woman from taking care of her baby, perform her daily activities. Weight gain is one of the predisposing factors that increases the possibility of developing rectus diastasis postpartum. Being obese increases liability to have rectus diastasis as carrying excess abdominal fats puts greater pressure against linea alba and can develop or aggravate symptoms for both men and women. This massively displaces the center of gravity anteriorly, disturbs body balance, increases joint loads and influences negatively pelvis posture leading to increased anterior pelvic tilt with subsequent exaggerated lumbar hyperlordosis. Ultrasound cavitation is the most revolutionary method that destroys excess body fat through creating microbubbles and releasing energy that breaks down fat cells. This trial has two groups: one will be treated by low caloric diet regimen only and the second one will be treated by ultrasound cavitation in addition to low caloric diet regimen for eight weeks


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date August 9, 2023
Est. primary completion date August 9, 2023
Accepts healthy volunteers No
Gender Female
Age group 25 Years to 35 Years
Eligibility Inclusion Criteria: 1. All women had a diastasis recti more than 2.5 cm and less than 4 cm in supra umbilical region. 2. Their ages were ranged from 25: 35 years. 3. Their BMI was more than 30 Kg/ m2. 4. All women were with lumbar hyperlordosis. 5. All women were multipara. 6. Their mode of delivery was normal vaginal delivery. 7. They were selected from 2: 5 months postnatal. Exclusion Criteria: 1. Previous cesarean section. 2. Previous abdominal and/ or back operation. 3. Spinal disorders. 4. Abdominal skin diseases. 5. Serious diseases such as heart disease, pace maker, uncontrolled diabetes or hypertension, autoimmune disease, malignancy, gastric ulcer, liver or renal failure and any other contraindication for body sculpting-weight loss.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
low caloric diet regimen
lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
Device:
ultrasound cavitation
patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks

Locations

Country Name City State
Egypt Asmaa Maher Ahmed Zahran Giza

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Static postural balance The Biodex Balance System SD (model: TP-3040-15, DC input: 19V-6.32A, connected to computer software version 4.0.06, 2017, serial number: R712010010, made in Taiwan) will be used to measure overall stability index of static postural balance for all patients up to eight weeks
Primary Dynamic postural balance The Biodex Balance System SD (model: TP-3040-15, DC input: 19V-6.32A, connected to computer software version 4.0.06, 2017, serial number: R712010010, made in Taiwan) will be used to measure overall stability index of dynamic postural balance for all patients up to eight weeks
Secondary Abdominal subcutaneous fat thickness Ultrasound imaging unit (Mindary DP10, linear probe, with 10 MHz frequency, serial number: bn- 75013216, made in China) will be used to measure abdominal subcutaneous fat thickness at the umbilical level from supine lying position for all patients up to eight weeks
Secondary Inter recti distance Ultrasound imaging unit (Mindary DP10, convex probe, with 5 MHz frequency, serial number: bn- 75013216, made in China) will be used to measure resting inter recti distance 2.5 cm above the upper margin of umbilicus from crock lying position for all patients up to eight weeks
Secondary Lumbar lordotic angle Spinal mouse (MEDIMOUSE) IDIAG M360 pro, pc-Software, 7.4.0., serial number: *112D2A24*, made in Switzerland) will be used to measure lumbar lordotic angle from standing position up to eight weeks
See also
  Status Clinical Trial Phase
Completed NCT05446675 - Endoscopic eTEP Versus Open Rives-Stoppa
Withdrawn NCT05229692 - Effect of Neuromuscular Electrical Stimulation on the Post-Operative Abdominoplasty Patient. N/A
Recruiting NCT04182412 - Abdominal Rectus Diastasis (ARD) Reconstruction N/A
Completed NCT05287282 - Impact of TECAR in Treatment of Rectus Diastasis N/A